1,026 results on '"Valent A"'
Search Results
2. Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
3. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience from the US Myeloma Innovations Research Collaborative (USMIRC)
4. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)
5. Characterization of Patients with Clonal Mast Cells in the Bone Marrow with Clinical Significance Not Otherwise Specified
6. 1112 Prevalence rates of chronic hypertension and hypertensive disorders of pregnancy: US national trends 2015-2020
7. 600 Does Mild Gestational Diabetes Increase Risk for Adverse Maternal Pregnancy Outcome?
8. 27 Relationship between metformin use and preterm preeclampsia in pregnancies with type 2 diabetes
9. 474 Association of diabetic ketoacidosis with adverse maternal outcomes for pregnant patients with pre-existing diabetes
10. Safety And Tolerability Of Cael-101, An Anti-amyloid Monoclonal Antibody, Combined With Anti-plasma Cell Dyscrasia Therapy In Patients With Light-chain Amyloidosis: 18-month Results Of A Phase 2 Study
11. 403 Associations between diabetic keto acidosis and adverse neonatal outcomes in those with pre-gestational diabetes
12. Strain-Induced Shape Transition of Vsi2 Cluster on Si(111)
13. 475 Delivery hospitalization costs associated with diabetic ketoacidosis among pregnant patients with pre-existing diabetes
14. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
15. Modern suicide trend from Internet
16. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
17. Affective temperament, fatigue, and pain in cancer patients
18. KIT Mutations and Other Genetic Defects in Mastocytosis
19. Filamentous pathogen effectors enter plant cells via endocytosis
20. The impact of COVID-19 and socioeconomic status on psychological distress in cancer patients
21. Medications for Managing Preexisting and Gestational Diabetes in Pregnancy
22. P-330 The third-generation genetic engineered mouse model of late-stage multiple myeloma
23. P-256 Initial report of a single institution experience with teclistamab for relapsed or refractory multiple myeloma including prior BCMA
24. [Translated article] Have changes concerning carboplatin and anthracyclines been incorporated?
25. Guías antieméticas: ¿hemos incorporado los cambios referentes a carboplatino y antraciclinas?
26. P-465 Global disparities in multiple myeloma: examining adverse events and drug toxicity trends
27. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma
28. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
29. Increased TIM-3 and GAL-9 serum levels in patients with advanced systemic mastocytosis
30. World Health Organization Classification and Diagnosis of Mastocytosis
31. Electrical Dyssynchrony in Cardiac Amyloidosis: Prevalence, Predictors, Clinical Correlates, and Outcomes
32. Cancer – A devastating disease, but also an eye-opener and window into the deep mysteries of life and its origins
33. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
34. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
35. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
36. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
37. The Role of Near Infrared Spectroscopy in Diagnosing Stump Ischaemia in Patients with Below Knee Amputation: Case Reports
38. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
39. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
40. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
41. Genetic Variants Leading to Urticaria and Angioedema and Associated Biomarkers
42. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: ACCELERATED FAILURE TIME MODELS AS A CLINICALLY PLAUSIBLE WAY TO DESCRIBE SURVIVAL IN MDS – AN ANALYSIS OF THE IWG-PM DATABASE
43. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES
44. Improvement Of Hemodynamic Profiling In Relation To Prognosis In Cardiac Amyloidosis
45. Importance Of Electrical Dyssynchrony In Cardiac Amyloidosis
46. European Competence Network on Mastocytosis (ECNM) : 20-Year Jubilee, Updates, and Future Perspectives
47. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?
48. Medications for Managing Preexisting and Gestational Diabetes in Pregnancy
49. The Characteristics of Multiple Myeloma Patients Referred for CAR T-Cell Therapy
50. Incidence of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.